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Low treatment efficacy represents an important unmet need in neuropathic pain patients 
and there is an urgent need to develop a more effective pharmacotherapy. An increasing 
number of patients choose complementary medicine to relieve pain. Lavender essential 
oil (LEO) is approved by the European Medicines Agency as herbal medicine to relieve 
anxiety and stress. However, the capability of LEO to relieve other nervous system disorders 
such as neuropathic pain has never been established. Our work aimed to evaluate the 
antineuropathic properties of lavender on a spared nerve injury (SNI) model of neuropathic 
pain in mice. An acute oral administration of LEO (100 mg/kg) alleviated SNI-induced 
mechanical allodynia, evaluated in the von Frey test, with an intensity comparable to the 
reference drug pregabalin. Investigations into the mechanism of action showed that LEO 
markedly decreased the phosphorylation of ERK1, ERK2, and JNK1, and decreased the 
levels of iNOS in the spinal cord; involvement of the endocannabinoid system was also 
detected using in vitro inhibition of the FAAH and MALG enzymes as well as in vivo 
experiments with the CB1 antagonist. Conversely, no effect on P38 phosphorylation and 
NF-kB activation was detected. These antihyperalgesic effects appeared at the same 
dose able to induce antidepressant-like, anxiolytic-like, and anorexic effects. In addition, 
gavage with LEO did not significantly alter animals’ gross behavior, motor coordination, 
or locomotor activity, nor impaired memory functions. Oral administration of LEO could 
represent a therapeutic approach in the management of neuropathic pain states.
Keywords: lavender essential oil, central nervous system, neuropathic pain, anxiety, depression, memory, feeding
INTRODUCTION
Neuropathic pain involves a lesion or disease of the nervous system and comprises numerous 
chronic pain conditions that involve different pathophysiological mechanisms (Cohen and Mao, 
2014). The neuropathic pain management is challenging. Despite the availability of numerous 
treatment options, many patients suffer from pain that is refractory to available treatments. 
Evaluation of pharmacotherapy in randomized clinical trials showed that clinically significant 
pain relief was experienced only by half of patients, which is predominantly partial but not 
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complete relief. In addition, patients very often experience 
heavy side effects, and as a consequence, they discontinue 
therapy (Vranken, 2012; Finnerup et  al., 2015). Inappropriate 
response to drug treatment represents an important unmet 
need in neuropathic pain patients. Therefore, there is an urgent 
need to develop novel and more effective therapies for 
this condition.
An increasing number of patients choose complementary 
or alternative medicine to relieve pain. Herbal medicines, 
commonly considered by population safer than conventional 
medicines, are widely used worldwide with more than 80% 
of the population consuming them for major and minor illnesses, 
particularly in developing countries (Ekor, 2014). Aromatherapy 
is one of the most widely used complementary therapies (Kyle, 
2006); this discipline is based on the medicinal uses of essential 
oils extracted from aromatic plants, which can be  absorbed 
through the skin (massage), the olfactory system (inhalation), 
or by oral administration (Buckle, 2014).
Lavender is one of the most popular essential oils used in 
aromatherapy. There are many different botanical species 
corresponding to the Lavandula genus but some of the species 
considered as medicinal are the following: Lavandula angustifolia, 
known as English lavender; L. stoechas, known as French 
lavender; L. latifolia, a Mediterranean grass-like lavender; and 
L. intermedia, which is a sterile cross between L. latifolia and 
L. angustifolia. The various lavenders have almost identical 
traditional uses and a large similarity in the main chemical 
constituents (Cavanagh and Wilkinson, 2002).
L. angustifolia Mill. is well known and appreciated by the 
cosmetic, food, and pharmaceutical industry as an aromatic 
and medicinal herb. Lavender essential oil is largely sold as 
over-the-counter herbal medicine for the treatment of depression, 
anxiety, and stress, and international organizations, including 
the World Health Organization (WHO), the European Medicines 
Agency (EMA), and the European Scientific Cooperative on 
Phytotherapy (ESCOP), approved lavender to ease anxiety, 
stress, and restlessness; a recent systematic review has also 
validated L. angustifolia essential oil for the treatment of 
generalized anxiety disorder (Barić et  al., 2018).
Lavender is also used in many countries as complementary 
therapy for painful and inflammatory conditions (Djenane 
et  al., 2012). Several clinical studies have reported that 
aromatherapy massage or inhalation with lavender produces 
pain relief in patients with different types of acute pain states, 
including pediatric pain (Soltani et  al., 2013), dysmenorrhea 
(Ou et al., 2012), cesarean postoperative (Olapour et al., 2013), 
labor (Yazdkhasti and Pirak, 2016), and in inflammatory 
disorders, such as osteoarthritis (Nasiri et  al., 2016). However, 
the capability of lavender essential oil to relieve neuropathic 
pain and its potential mechanisms has never been elucidated. 
This study aims to investigate the antineuropathic properties 
of lavender in a mouse model of neuropathic pain. Mood 
disorders, such as depression and anxiety, are frequently 
experienced by patients suffering from neuropathic pain (Langley 
et al., 2013). Epidemiologic studies reported approximately 34% 
mean prevalence rate for major depressive disorder in neuropathic 
patients (Gustorff et al., 2008) and clinical studies have indicated 
strong comorbidity between chronic pain and anxiety (Scott 
et al., 2007; Tsang et al., 2008). The induction of an antidepressant/
anxiolytic action, along with an anti-allodynic activity, might 
improve the overall condition of patients and produce important 
clinical benefits. The capability of LEO to induce antidepressant/
anxiolytic effects at analgesic doses is, thus, here investigated.
Finally, the induction of additional pharmacological or 
toxicological behavioral effects by the essential oil is also 
investigated in order to better define the lavender pharmacological 
and safety profile.
MATERIALS AND METHODS
Animals
Experiments were performed on male CD1 mice (weight: 
22–24 g; Harlan Laboratories, Bresso, Italy). Mice were randomly 
housed in standard cages and kept in a room at 23  ±  1°C 
with a 12-h light/dark cycle, light on at 7  a.m. Food (standard 
laboratory diet) and tap water were available ad libitum. The 
cages were placed in the experimental room 24  h before 
behavioral testing for acclimatization. All tests were conducted 
during the light phase. The experimental protocol was approved 
by the Institution’s Animal Care and Research Ethics Committee 
(University of Florence, Italy), under license from the Italian 
Department of Health (54/2014-B). Mice were treated in 
accordance with the relevant European Union (Directive 2010/63/
EU, the council of 22 September 2010 on the protection of 
animals used for scientific purposes) and international regulations 
(Guide for the Care and Use of Laboratory Animals, US National 
Research Council, 2011). All studies involving animals are 
reported in accordance with the ARRIVE guidelines for 
experiments involving animals (McGrath and Lilley, 2015). The 
experimental protocol was designed to minimize the number 
of animals used and their suffering.
The number of animals per experiment was based on a 
power analysis (Charan and Kantharia, 2013). For behavioral 
assays, 10 animals per group were used to have the probability 
of 86% at which the study detects a difference between groups 
(0.05 significance level). A G power software was used to 
calculate sample size.
Chemicals and Drug Administration
Pure lavender (L. angustifolia) essential oil (LEO) was kindly 
supplied by Pranarom International (Belgium). According to 
the GC-MS analyses performed by Pranarom, lavender essential 
oil (LEO) showed the following composition: linalyl acetate 
(35.96%), linalool (35.29%), β-caryophyllene (3.37%), trans-β-
ocimene (2.88%), cis-β-ocimene (2.67%), lavandulyl acetate 
(2.29%), and terpinen-4-ol (1.94%).
Mice were randomly assigned to each treatment group by 
a researcher other than the operator. LEO was diluted in 5% 
DMSO and administered p.o. 30  min before testing at the 
Abbreviations: i.p., Intraperitoneal; FAAH, Fatty acid amide hydrolase; LEO, 
Lavender essential oil; MAGL, Monoacylglycerol lipase; NORT, Novel object 
recognition test; p.o., Per os; SNI, Spared nerve injury; TST, Tail suspension test.
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dose of 100 mg/kg for all experiments except for dose-response 
curve where doses of LEO ranging from 10 to 200  mg/kg 
p.o. were used. The control group received equivalent volume 
of the vehicle.
Pregabalin (30  mg/kg  i.p.) (Sigma, Milan, Italy) was 
administered 3  h before testing; citalopram hydrobromide 
(10  mg/kg  i.p.), AM251 (4  mg/kg  i.p.) (Tocris, Bristol, UK), 
diazepam (1  mg/kg  i.p.), and amitriptyline (10  mg/kg  i.p.) 
(Sigma, Milan, Italy) were administered 30  min before tests; 
morphine hydrochloride (7 mg/kg  i.p.) (SALARS, Como, Italy) 
was administered 15  min before testing. The abovementioned 
reference drugs were dissolved in saline solution with the 
exception of AM251 that was prepared in a vehicle of dimethyl 
sulfoxide/Tween 80/0.9% saline (1:1:18). Treatments were 
administered in a volume of 10  ml/kg by gavage (p.o.) or 
intraperitoneal (i.p.) administration.
Behavioral tests on spared nerve injury (SNI) animals were 
performed on postoperative day 7. Samples to perform in vitro 
assays were harvested on postoperative day 7, 30  min after 
lavender oil administration.
Nociceptive Behavior
Spared Nerve Injury
Behavioral testing was performed before surgery to establish 
a baseline for comparison with postsurgical values. The SNI 
procedure was applied as described by Bourquin et  al. (2006). 
Mice were anesthetized (sodium pentobarbital 60  mg/kg  i.p.) 
and placed in a prone position. An incision was made on the 
lateral surface of the thigh and a section was made directly 
through the biceps femoris muscle and the three branches of 
the sciatic nerve, the sural, common peroneal, and tibial nerves, 
were exposed. Both tibial and common peroneal nerves were 
ligated together (5.0 silk, Ethicon; Johnson & Johnson Intl, 
Brussels, Belgium) and transected approximately 2  mm distal 
to the ligation. The sural nerve was left intact. The muscles 
and skin were closed using a 5.0 silk suture. Sham-operated 
mice underwent the same procedure except ligation and 
transection of the nerves. Intense, reproducible, and long-lasting 
thermal and mechanical hypersensitivity is measurable in the 
non-injured sural nerve skin territory. Nociceptive threshold 
was measured on postsurgical day 7.
Mechanical Threshold (von Frey’s Test)
Mechanical allodynia was measured by using a Dynamic Plantar 
Aesthesiometer (Ugo Basile, Bologna, Italy) as previously 
described (Sanna et al., 2015). The mice were placed in individual 
Plexiglas chambers [8.5 × 3.4 × 3.4 (h) cm] on a wire-mesh 
grid floor and an adaptation period of approximately 1  h was 
allowed, during which exploratory and grooming activity ended. 
After that, a mechanical stimulus was delivered to the plantar 
surface of the hind paw of the mouse, using an automated 
transducer filament. A steel rod (2  mm) was pushed with 
electronic ascending force (0–5  g in 35  s). The pain threshold 
was defined as the amount of pressure, recorded to the nearest 
0.1  g, that induced a flexor response and was determined by 
three repeated challenges at 10-min intervals. The averages of 
responses were calculated. Nociceptive response for mechanical 
sensitivity was expressed as paw withdrawal threshold (g) and 
both ipsilateral (operated) and contralateral (unoperated) hind 
paws were tested.
Hot Plate Test
The hot plate test was performed as previously described (Sanna 
et  al., 2015). Mice were placed on a hot plate (Ugo Basile 
Biological Research Apparatus, Varese, Italy), with the temperature 
adjusted to 52.5  ±  0.1°C. Reaction latencies (s) were measured 
with a stopwatch before (baseline latency) and after treatments. 
The time to the first sign of nociception (paw licking) was 
recorded and the mouse immediately removed from the hot 
plate. An arbitrary cutoff period of 45 s was adopted to avoid 
damage to the paws.
Locomotor Activity
Rotarod Test
Motor performance was evaluated using the rotarod test (Galeotti 
et al., 2003). The rotarod apparatus consisted of a 3-cm-diameter 
rod with a non-slippery surface at a rotation rate of 16 RPM. 
The rod, 30  cm in length, was placed at a height of 15  cm 
from the base and divided into 5 equal sections by 6 disks. 
The animal was placed back on the rod immediately after 
falling and the integrity of motor coordination was assessed 
as number of falls from the rod in 30  s.
Hole-Board Test
The spontaneous locomotor activity was evaluated by using 
the hole-board test (Galeotti et al., 2003). The apparatus consisted 
of an elevated arena (40  cm × 40  cm; 1  m above the floor) 
with 16 evenly spaced holes (3  cm diameter; four lines of 
four holes each). Mice were placed individually on the center 
of the board and allowed to explore the plane freely for a 
period of 5  min each. Movements of the animal on the plane 
(spontaneous mobility) were automatically recorded by two 
photobeams, crossing the plane from midpoint to midpoint 
of opposite sides, thus dividing the plane into four equal 
quadrants. Miniature photoelectric cells, in each of the 16 
holes, recorded the head-dips in the holes by the mice. This 
head-dipping behavior represents the exploratory activity of mice.
Antidepressant-Like Activity
Tail Suspension Test
The tail suspension test was performed according to Galeotti 
and Ghelardini (2012). Mice were suspended from a plastic 
rod mounted 50  cm above the floor by adhesive tape placed 
to the upper middle of the tail. The time during which mice 
remained immobile was measured with a stopwatch during a 
test period of 6  min. Mice were considered immobile when 
they hung passively and completely motionless, except movements 
caused by respiration. Immobility was considered as depression-
like behavior (behavioral despair) and was measured in the 
first 2  min of the test, when animals react to the unavoidable 
stress, and in the last 4  min, when the behavioral despair 
is established.
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Evaluation of Food Consumption
Feeding behavior was assessed in mice with no food provided 
for 4  h but water was available ad libitum. A weighed amount 
of food (standard laboratory pellets) was given to mice and the 
weight of the food consumed (difference between the given 
amount of food and that left in the cage, including spillage) was 
measured after 15, 30, 45, and 60  min, to an accuracy of 0.1  g.
Evaluation of Mnemonic Functions
Novel Object Recognition Test
Memory-related responses were measured using the novel object 
recognition test (NORT), which is based on natural exploratory 
activity of mice. NORT evaluates the rodent’s ability to recognize 
a novel object in the environment and measures a form of 
recognition memory (Okamura et  al., 2011). To perform the 
NORT, an open field device (cylinder diameter: 78  cm, height 
walls: 60  cm) was used. Mice were allowed to explore the 
open field. No object was placed in the box during the habituation 
session. Then, in the first session (training phase), animals 
were placed in the middle of the arena and presented with 
two identical objects (A1 and A2), placed 16  cm from the 
wall and 37  cm apart, for 5  min. Object exploration was 
measured manually using a stopwatch by an experienced observer 
blind to drug treatment. Exploration was defined as sniffing 
or touching the object with the nose or mouth. To measure 
short-term memory or long-term memory, the animals were 
placed back in the open field after 3-h or 24-h delay in the 
home cage, respectively, and presented with two objects, the 
familiar A1 (the same as the training phase) and a novel 
object B for 5 min (test phase). The objects were always placed 
in the same location. To secure the objects in place, Velcro 
into the base of the objects was used. Objects A1 and B had 
different shapes, colors, and sizes that had no significance for 
animals. The objects and the apparatus were cleaned with 
ethanol solution between trials to remove the olfactory cues. 
The test phase reflects the preference for the novel object. 
Recognition index for the novel object was calculated (TN-TF/
TN  +  TF) × 100 (TF  =  time spent exploring familiar object; 
TN  =  time spent exploring the novel object). During the 
training session, both objects are novel and the time spent 
on both objects should be  similar.
Anxiolytic-Like Activity
Light-Dark Box
The light-dark box apparatus (length 50  cm, width 20.5  cm, 
and height 19 cm) consisted of two equal acrylic compartments, 
one dark (black) and one illuminated by a 60-W bulb lamp 
(white). A dark insert (with black walls and lid, nontransparent 
for visible light) was used to divide the arena into two equal 
parts. The two compartments communicated by a small door 
(10  cm × 3.2  cm) at floor level in the wall of the insert that 
allowed animals to move freely from one compartment to 
another. Each mouse was released in the center of the light 
compartment with its head facing away from the door and 
allowed to explore the arena for 5  min. Behavioral parameters 
recorded were the latency to the first step into the dark 
compartment, the time spent in the light chamber and the 
number of full-body transitions between chambers since 
previously described as a reflection of anxiety in this apparatus 
(Bourin and Hascoët, 2003). After testing, animals were removed 
from the light-dark box and returned to their home cage in 
colony room. After each test, the apparatus was cleaned with 
70% ethanol to remove the olfactory cues and allowed to dry 
before the next subject was tested. This test exploited the 
conflict between the animal’s tendency to explore a new 
environment and its fear of bright light.
Preparation of Membranes
Spinal cord samples from control and SNI mice were rapidly 
isolated and frozen in liquid nitrogen or stored at 80°C. The 
frozen spinal cords were homogenized in a lysis buffer. The 
homogenate was centrifuged at 9,000 × g for 15  min at 4°C, 
the low-speed pellet was discarded and the supernatant (total 
proteins) was stored at −80°C. Protein concentration was 
quantified using Bradford’s method (protein assay kit, Bio-Rad 
Laboratories, Milan, Italy).
Western Blot Analysis
Membrane homogenates (20–50  μg) were separated on 10% 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE). The resolved proteins were transferred onto 
polyvinylidene difluoride (PVDF) membranes (120  min at 
100  V) using standard procedures. Membranes were blocked 
in PBST (PBS containing 0.1% Tween) containing 5% nonfat 
dry milk for 120  min and then rinsed three times in Washing 
Buffer for 5  min each. Membranes were incubated overnight 
at 4°C with specific antibodies against ERK1/2 (1:1,000); ERK/1/2 
phosphorylated on Thr202/Tyr204 (p-ERK1/2; 1:1,000); iNOS 
(1:250); Iκ-Bα (1:1,000) (Santa Cruz Biotechnology Inc, CA, 
USA); p38MAPK (1:500); p38MAPK phosphorylated onThr180/
Tyr182 (p-p38 MAPK, 1:250); JNK (1:750); JNK phosphorylated 
on Thr183/Tyr185 (p-JNK, 1:750) (Cell Signalling Technology, 
MA, USA). The blots were rinsed thrice in PBS containing 
0.1% Tween and incubated with goat anti-rabbit horseradish 
peroxidase-conjugated secondary antisera (1:10,000) and left 
for 1 h at room temperature. Blots were then extensively rinsed, 
followed by visualization using chemiluminescence detection 
system (Pierce, Milan, Italy) and signal intensity (pixels/mm2) 
quantified (ImageJ, NIH). Original blots are reported in 
Supplementary Figure 1. Exposition and developing time used 
was standardized for all the blots. For each sample, the signal 
intensity was normalized to that of ß-actin (Santa Cruz 
Biotechnology, CA, USA), used as loading control for protein 
expression, and the expression level of the proteins is an average 
of the densities per band area from each group.
In vitro Inhibition of Fatty Acid Amide 
Hydrolase and Monoacylglycerol Lipase
The in vitro direct inhibition of the FAAH enzyme was measured 
by a fluorescence procedure using a Synergy H1 hybrid 
multimode reader (Biotek) and following manufacturer’s 
instructions of a commercial kit (Cayman, item no. 10005196). 
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JZL 195 (CAS: 1210004-12-8), provided by Cayman, was used 
as reference inhibitor.
The inhibition of the MAGL enzyme was evaluated using 
the same Biotek reader by a colorimetric procedure following 
manufacturer’s instructions of a commercial kit (Cayman, item 
no. 705192) with the same reference inhibitor JZL 195. In 
both cases, LEO was dissolved in DMSO at various concentrations.
Statistical Analysis
Data are expressed as the mean ± s.e.mean. For Western blotting 
assays, data are mean of four individual experiments conducted 
in duplicate. Statistical analysis was performed using Student’s 
t-test, one-way ANOVA (followed by Tukey’s test for post hoc 
comparison) or two-way ANOVA (followed by Bonferroni test 
for post hoc analysis). Mean differences with p  <  0.05 were 
considered statistically significant. To conduct statistical analyses, 
the computer program GraphPad Prism version 5.0 (GraphPad 
Software Inc., San Diego, CA, USA) was used.
RESULTS
Antinociceptive Activity of Lavender 
Essential Oil
The antinociceptive activity of lavender essential oil (LEO) was 
evaluated against conditions of acute and persistent nociception 
and the modulation of the pain threshold was evaluated by 
applying a thermal (hot plate test) or a mechanical (von Frey’s 
test) stimulus. A dose-response study showed that LEO produced 
a dose-related antinociceptive activity against an acute thermal 
stimulus. The doses of 10 and 50 mg/kg were ineffective. Although 
not significant, the dose of 75  mg/kg  slightly increased the pain 
threshold whereas the dose of 100  mg/kg reached a significant 
antinociceptive activity. No further increase was detected at 
higher doses (Figure 1A). Time-course experiments showed that 
the antinociceptive effect of LEO 100  mg/kg peaked 30  min 
after administration and then rapidly diminished disappearing 
at 45 min (Figure 1B). The increase of pain threshold produced 
by LEO 15 and 30  min after administration was of intensity 
comparable to that produced by morphine 7 mg/kg s.c. (Figure 1B).
The antinociceptive activity of LEO was also investigated in 
the presence of a condition of persistent pain by using a model 
of neuropathic pain (SNI model) in mice. Seven days after surgery, 
SNI mice showed a marked mechanical hyperalgesia on the 
ipsilateral side in comparison with the contralateral uninjured 
side (Figure 1C). Treatment with LEO 100  mg/kg completely 
prevented mechanical allodynia in the ipsilateral side without 
any effect on the nociceptive threshold of the contralateral side 
with respect to values before treatment. The intensity of the 
antihyperalgesic effect produced by LEO was comparable to that 
induced by pregabalin, used as reference drug. Amitriptyline was 
used as negative reference drug and resulted ineffective (Figure 1C).
A B
C
FIGURE 1 | Antinociceptive profile of LEO. (A) A dose-response curve showed antinociceptive activity of LEO (10–200 mg/kg p.o.) against an acute thermal stimulus 
(hot plate test). (One-way ANOVA, F(5,59) = 23.51, p < 0.0001); p < 0.05; p < 0.001. (B) Time-course experiments with LEO (100 mg/kg p.o.) in comparison with 
morphine (7 mg/kg i.p.) in the hot plate test. (Two-way ANOVA, treatment F(2,135) = 41.08, p < 0.0001; time F(4,135) = 17.11, p < 0.001); *p < 0.05, **p < 0.01, 
***p < 0.001 vs. control group. (C) Mice that underwent spared nerve injury (SNI) showed mechanical allodynia in the ipsilateral side in comparison with the 
contralateral side, on day 7 after surgery. LEO (100 mg/kg p.o.) prevented mechanical hypersensitivity. Pregabalin (30 mg/kg i.p.) and amitriptyline (10 mg/kg i.p.) were 
used as reference drugs. (One-way ANOVA, F(7,79) = 28.38, p < 0.0001); **p < 0.01, ***p < 0.001 vs. contralateral side; °°p < 0.01, °°°p < 0.001 vs. ipsilateral side.
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A B
C D
FIGURE 2 | Effect of LEO on MAPK phosphorylation in the spinal cord of SNI mice. LEO (100 mg/kg p.o.) prevented the increase in the phosphorylation of ERK1 
(one-way ANOVA, F(2,17) = 31.07, p < 0.0001) (A), ERK2 (one-way ANOVA, F(2,17) = 30.81, p < 0.0001) (B), and JNK1 (one-way ANOVA, F(2,17) = 9.80, 
p < 0.001) (C) induced by SNI 7 days after surgery. (D) Lack of effect of LEO on P38 increased phosphorylation (one-way ANOVA, F(2,17) = 23.73, p < 0.0001). 
Representative blots were reported in each panel. *p < 0.05, **p < 0.01, ***p < 0.001 vs. sham-operated control group. °p < 0.05, °°°p < 0.001 vs. SNI.
Effect of Lavender Essential Oil on the 
Phosphorylation of MAPK
Large evidence indicates that MAPKs participate in the spinal 
mechanisms of neuropathic pain. Following LEO treatment, 
the levels of phosphorylation of ERK, JNK, and P38 within 
spinal cord of neuropathic mice were investigated in order 
to exploit the cellular pathway modulated by LEO in 
SNI animals.
Experiments performed in spinal cord samples from the 
ipsilateral side of SNI mice, collected 7  days after surgery, 
showed an increase in the phosphorylation of both ERK1 
(Figure 2A) and ERK2 (Figure 2B) isoforms. This ERK1 and 
ERK2 over-phosphorylation was prevented by treatment with 
LEO 100  mg/kg.
The analysis of levels of pJNK illustrated an isoform-selective 
influence of the SNI surgery procedure on activation of JNK 
proteins. Although JNK1 and JNK2 are abundantly expressed 
in the spinal cord, for the active forms, pJNK1 (p46) is the 
predominant spinal form and pJNK1 levels in the spinal cord 
selectively increase after nerve injury (Daulhac et  al., 2006; 
Zhuang et  al., 2006). In agreement with these studies, SNI 
mice showed increased levels of pJNK1. No band corresponding 
to pJNK2 molecular weight was detected. Treatment with LEO 
prevented the pJNK1 phosphorylation (Figures 2C,D).
An increase of p-P38 contents was observed in the spinal 
cord of SNI mice 7  days after surgery (Figure 2D). Converse 
to what was observed for ERK and JNK, treatment with LEO 
did not produce any variation in the levels of phosphorylated 
P38 MAPK (Figure 2D).
The expression of total ERK1/2, JNK1/2, and P38 was not 
significantly modified in spinal cord samples from SNI mice 
and no effect was produced by LEO administration (Figure 2).
Effect of Lavender Essential Oil on the 
Activation of Inducible NO Synthase
Spinal neuroimmune and neuroinflammatory activities have 
been demonstrated to participate in neuropathic pain. Specifically, 
pro-inflammatory cytokines, such as IL-1, IL-6, TNF-α, and 
iNOS have been largely demonstrated to be  involved in the 
onset and development of inflammatory and neuropathic pain 
(He et  al., 2014). In the present study, SNI increased the 
expression of iNOS at day 7. Treatment with LEO 100  mg/kg 
significantly decreased the levels of iNOS compared to the 
SNI-treated group (Figure 3A).
Lack of Effect of Lavender Essential Oil on 
the Activation of the NF-κB Pathway
To investigate transcriptional mechanisms that promote iNOS 
expression, the activation of NF-κB in SNI mice was examined 
by immunoblotting experiments. Under basal conditions, NF-κB 
is inhibited by the inhibitory subunit IκBα. Following 
phosphorylation and degradation of IκBα, NF-κB is released 
and translocates to the nucleus, promoting gene transcription. 
SNI mice showed a significant decrease of IκBα protein levels, 
indicating the degradation of the NF-κB inhibitory subunit, 
7  days after surgery. However, LEO administration did not 
modify the IκBα levels indicating that it was unable to prevent 
the activation of the NF-κB pathway (Figure 3B).
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Involvement of the Endocannabinoid 
System: In vitro Inhibition of Fatty Acid 
Amide Hydrolase and Monoacylglycerol 
Lipase Enzymes and in vivo Pre-treatment 
With the CB1 Receptor Antagonist AM251
In order to detect the potential implication of the endocannabinoid 
system in the analgesic activity of LEO, inhibition of the FAAH 
and MAGL enzymes was tested. LEO showed a dose-dependent 
response in the enzymatic bioassays (Figure 4A). The reference 
substance JZL 195 provided by Cayman showed a very similar 
profile both in the FAAH and MAGL enzymes with an IC50 
value between 0.01 and 0.1  μM (Figure 4B). LEO was less 
potent than the inhibitor but was able to inhibit both enzymes, 
particularly FAAH (Figure 4A). Pre-treatment with the CB1 
receptor antagonist AM251 (4  mg/kg) significantly attenuated 
LEO-induced anti-allodynic effect (Figure 4C).
Antidepressant-Like Activity of Lavender 
Essential Oil in a Depressant-Like Paradigm
The effect of LEO in a depressant-like behavior task was 
investigated in the tail suspension test (TST), one of the most 
widely used models for evaluating antidepressant-like activities 
in mice. Immobility developed by animals subjected to the 
short-term, unavoidable stress of being suspended by their tail 
is considered as a depressive-like behavior. The presence of 
an antidepressant-like phenotype is detected in the last 4  min 
of the test, when the behavioral despair is established. LEO 
decreased the immobility time values showing an antidepressant-
like activity. The administration of citalopram, a reference 
antidepressant drug, reduced the immobility time values with 
an intensity comparable to that of LEO (Figure 5A).
Anxiolytic-Like Activity of Lavender 
Essential Oil
The effect produced by LEO on anxiety-related behaviors 
was investigated by using the light-dark box test. Mice 
treated with LEO 100  mg/kg took less time to leave the 
dark compartment and spent significantly more time in the 
light chamber, thus evidencing anxiolytic-like properties. 
The anxiolytic compound diazepam was used as a positive 
reference drug. Diazepam prolonged the time spent in 
the lighted compartment producing an anxiolytic effect 
comparable to that induced by LEO (Figure 5B). The number 
of transitions between two boxes was a second behavioral 
parameter detected to evaluate the presence of an anxiolytic-
like behavior. This parameter was significantly increased 
after LEO administration in comparison with the control 
group. This effect was comparable to that produced by 
diazepam (Figure 5C). All these data indicate an anxiolytic-
like activity of LEO in mice.
Anorexic Effect of Lavender Essential Oil
The feeding behavior of mice treated with LEO 100  mg/kg 
was evaluated in animals that were previously deprived of 
food for 4  h, an experimental condition suitable to highlight 
both an increase and a decrease in food consumption. In 
Figure 5A is illustrated the cumulative curve for the food 
eaten by mice. Control mice showed a progressive increase 
of food intake in 60  min. Similarly, LEO-treated progressively 
increased the food consumption, but the cumulative amount 
of food eaten over the 60-min period of the test was significantly 
lower than control group, showing an anorexic phenotype 
(Figure 6A). The effect on feeding behavior disappeared 60 min 
after treatment, similar to what was observed for the 
antinociceptive activity.
Lack of Impairment of Locomotor 
Behavior
Mice treated with LEO 100 mg/kg did not show any alteration 
in gross behavior or visible sign of poor health. In addition, 
specific tests were conducted to reveal locomotor alterations 
not visible to the operator. The rotarod test was used to evaluate 
motor coordination and the hole-board test to evaluate 
spontaneous mobility and exploratory activity of treated mice.
A B
FIGURE 3 | Effect of LEO on iNOS and NF-kB in the spinal cord of SNI mice. LEO (100 mg/kg p.o.) prevented the increased expression of iNOS (A) induced by 
SNI 7 days after surgery (One-way ANOVA, F(2,17) = 133.30, p < 0.0001). (B) Lack of effect of LEO on Ik-Balpha decreased expression (One-way ANOVA, 
F(2,17) = 12.27, p < 0.001). Representative blots were reported in each panel. **p < 0.01, ***p < 0.001 vs. sham-operated control group. °°°p < 0.001 vs. SNI.
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The number of falls from the rotating rod was comparable 
to that of control mice, indicating that LEO did not impair 
motor coordination (Figure 6B). In addition, the spontaneous 
mobility (Figure 6C) and exploratory activity (Figure 6D) were 
unaltered by LEO administration in comparison with the 
control mice.
Lack of Effect of Lavender Essential Oil  
on Memory Functions
To investigate the effect of LEO treatment on memory processes, 
the behavioral response of treated mice in the novel object 
recognition test (NORT) was determined.
In the training session of the NORT (internal control), 
the total time spent exploring both objects by LEO-treated 
mice was comparable to that of the control mice group 
(Figure 7A). Similarly, LEO-treated mice showed no differences 
with control group in exploration times (Figure 7A). In the 
retention session, the evaluation of the exploration times 
between training object and novel object illustrated that 
LEO treatment increased novel object exploration time with 
an intensity comparable to that detected in control mice 
(Figure 7B). The training object exploration index (TOE), 
the novel object exploration index (NOE), and the 
discrimination index (DI) of LEO-treated mice were similar 
to those of control mice, showing that LEO administration 
did not produce any detrimental or ameliorative effect on 
recognition memory (Figure 7C).
DISCUSSION
Pharmacological treatment is the mainstay of neuropathic pain 
management. Although there is a great number of available 
analgesic treatments, the unsatisfactory efficacy and negative 
side effects of these drugs make effective pharmacotherapy of 
neuropathic pain still often unobtainable (Finnerup et  al., 
2015). Thus, inadequate response to analgesic drugs still 
represents a major unmet need in the management of neuropathic 
pain. In order to exploit new therapeutic interventions for 
neuropathic pain, in the present study, the antihyperalgesic 
activity of lavender essential oil (LEO) was investigated in an 
animal model.
A single oral administration of LEO reversed mechanical 
hypersensitivity in the spared nerve injury (SNI) model of 
neuropathic pain, increasing the pain threshold to values 
comparable to that produced by pregabalin, one of the few 
drugs approved and licensed for neuropathic pain used as 
reference compound. Present results give the first description 
of the capability of LEO to ameliorate hyperalgesia in 
neuropathic pain conditions after a single oral administration. 
A recent clinical study reported the efficacy of topical 
FIGURE 4 | of LEO (100 mg/kg p.o.) by the CB1 receptor antagonist AM251 
(4 mg/kg i.p.). (One-way ANOVA, F(5,59) = 24.29, p < 0.0001); *p < 0.05, 
***p < 0.001 in comparison with CTRL contralateral side; °°°p < 0.001 in 
comparison with CTRL ipsilateral side.
A
B
C
FIGURE 4 | Inhibition of fatty acid amide hydrolase (FAAH) and 
monoacylglycerol lipase (MAGL) performed by lavender essential oil (A) and 
the reference inhibitor JZL 195 (B). (C) Attenuation of the anti-allodynic effect 
(Continued)
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application of the essential oil of L. stoechas, another 
plant from the genus Lavandula, on reducing pain intensity 
in mild to moderate carpal tunnel syndrome, the most 
common entrapment neuropathy of the upper extremity 
(Eftekharsadat et al., 2017), further supporting the hypothesis 
of a positive effect of lavender essential oils in neuropathic 
pain conditions.
Several clinical evaluations showed analgesic efficacy of 
aromatherapy massage or inhalation with LEO in different 
types of acute pain (Ou et  al., 2012; Olapour et  al., 2013; 
Soltani et  al., 2013; Yazdkhasti and Pirak, 2016). To better 
define the antinociceptive profile of LEO, we  also tested the 
essential oil in a condition of acute thermal pain. In the 
hot plate test, LEO increased the pain threshold with an 
A B C
FIGURE 5 | Effect of LEO on depression and anxiety. (A) Antidepressant-like effect induced by LEO (100 mg/kg p.o.) in the tail suspension test. Citalopram (CIT; 
10 mg/kg i.p.) was used as antidepressant reference drug (one-way ANOVA, F(2,29) = 28.36, p < 0.0001). Anxiolytic-like activity of LEO showed by a reduction of 
the time spent in the light chamber (one-way ANOVA, F(2,29) = 14.42, p < 0.0001) (B) and by an increase in the number of transitions (one-way ANOVA, 
F(2,29) = 14.11, p < 0.0001) (C). Diazepam (DIA; 1 mg/kg i.p.) was used as anxiolytic reference drug; *p < 0.05, **p < 0.001 in comparison with control mice.
A B
C D
FIGURE 6 | Effect of LEO on feeding and locomotor behaviour. (A) The food consumption was evaluated as the cumulated amount of food eaten over a 60-min 
period in 4 h food-deprived mice. LEO (100 mg/kg p.o.) significantly decreased food consumption 30 min after administration. (two-way ANOVA, treatment F(1,48) 
16.72 p < 0.001; time F(2,48) 32.07 p < 0.0001); *p < 0.05 in comparison with control mice. Lack of impairment of motor coordination (B), spontaneous mobility 
(C), and exploratory activity (D) in mice treated with LEO.
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efficacy similar to that produced by morphine (7  mg/kg), 
in agreement with clinical data. Furthermore, the 
antinociceptive effect was produced after oral administration, 
indicating that the analgesic properties of LEO were not 
strictly related to aromatherapy massage or inhalation of 
the essential oil. These results show that orally administered 
LEO is endowed with both antihyperalgesic and 
analgesic properties.
MAPK is a family of proteins composed by three major 
members: extracellular signal-regulated kinases (ERK), P38, 
and c-Jun N-terminal kinase (JNK), which represent three 
separate signaling pathways. A large evidence shows that 
activation of MAPK signaling has a critical role in peripheral 
and central sensitization associated with neuropathic pain 
conditions (Ji et al., 2009; Edelmayer et al., 2014). To evaluate 
the mechanism of antinociceptive action of LEO in neuropathic 
pain, the role of MAPK was investigated in spinal cord 
preparations from SNI mice. As previously reported, SNI 
increases phosphorylation of all MAPK members, even if 
with a different pattern of activation (Sanna et  al., 2015). 
However, spinal ERK1, ERK2, P38, and JNK1, the predominant 
JNK active form in the spinal cord after nerve injury (Daulhac 
et al., 2006; Zhuang et al., 2006), were all over-phosphorylated 
7  days after injury. Oral administration of LEO prevented 
the increase of ERK1, ERK2, and JNK1 phosphorylation. 
Conversely, no reduction in the levels of pP38 was detected. 
These findings indicate a prominent modulation of spinal 
ERK and JNK activity by LEO, whereas P38 appears not 
to be  a key site of action for the LEO-induced anti-
allodynic effect.
Recently, a growing number of literature reports have 
described the role of neuroinflammation in the pathogenesis 
of neuropathic pain (Austin and Moalem Taylor, 2010; Calvo 
et al., 2012; He et al., 2014). Pro-inflammatory cytokines such 
as IL-1, IL-6, TNF-α, and nitric oxide (NO) have been involved 
in demyelination and degeneration of peripheral nerves, increase 
in excitability of sensory afferent, and strongly implicated in 
the initiation and development of neuropathic pain (Jancálek 
et  al., 2010; Ahlawat et  al., 2014; He et  al., 2014).
NO has been reported to participate in pain transmission. 
In addition, neuronal (nNOS), endothelial (eNOS), and 
inducible (iNOS) NO synthase (NOS), are upregulated in 
the nervous system under different pathological conditions, 
including neuropathic pain (Schmidtko et  al., 2009). There 
is strong evidence indicating the specific involvement of 
iNOS in the onset and progression of neuropathic pain. 
Among all isoforms, iNOS is most closely associated with 
inflammation and pain and its expression is increased in 
dorsal root ganglia and spinal cord in neuropathic pain 
states (Martucci et  al., 2008). SNI mice showed increased 
spinal levels of iNOS that were abolished by treatment with 
LEO. Since iNOS inhibitors have been indicated as useful 
for the treatment of neuropathic pain (De Alba et  al., 2006; 
LaBuda et  al., 2006; Ahlawat and Sharma, 2018), this anti-
inflammatory effect could, at least in part, explain the 
antinociceptive effects of LEO.
A B
C
FIGURE 7 | Lack of effect of LEO on memory processes. (A) In the training session of the novel object recognition test (NORT), no difference between exploration 
times was measured. (B) In the retention test, the exploration time of the familiar object was reduced in control group. LEO-treated mice (100 mg/kg p.o.) showed 
exploratory activity times similar to control mice. (C) LEO-treated mice showed a training object exploration index (TOE), novel object exploration index (NOE), and 
discrimination index (DI) comparable to control group. *p < 0.05 in comparison with training values (Student’s t-test).
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iNOS is under the transcriptional control of several 
transcription factors, including nuclear factor-κB (NF-κB) 
(Kleinert et  al., 2004). In the nervous system, NF-κB consists 
of homo- and heterodimers (p50/p65). Under basal conditions, 
NF-κB is mainly located within the cytoplasm and is complexed 
to the inhibitory subunit (IκB), keeping NF-κB in an inactive 
state. Following specific stimuli, IκB is phosphorylated and 
degraded. This process releases NF-κB and promotes its 
translocation from cytosol to the nucleus to modulate the 
expression of NF-κB-dependent inflammatory genes (Mincheva-
Tasheva and Soler, 2013). NF-κB triggers a self-perpetuating 
process resulting, progressively, in neuropathic pain and many 
small molecules have been reported to provide protection 
against neuropathic pain by blocking the NF-κB signaling (Lee 
et  al., 2011; Zhou et  al., 2014). However, LEO was unable to 
counteract the activation of NF-κB, indicating that this pathway 
is not prominently involved in the mechanism of antihyperalgesic 
activity of LEO.
New pharmacological treatments for pain are being 
developed based on molecular interactions with the 
endocannabinoid system (Woodhams et  al., 2017). Although 
phytocannabinoids from Cannabis sativa are ligands of the 
CB1 and CB2 receptors and are approved for certain 
pain conditions, the blockade of the endocannabinoids 
metabolism through FAAH and MAGL inhibition may be  a 
new analgesic approach for neuroinflammatory diseases 
(Chiurchiù et  al., 2018). This is the first time that LEO is 
reported as a potential FAAH/MAGL inhibitor, which could 
explain at least in part the analgesic effects in this model 
of neuropathic pain.
The main components of lavender are linalool, linalyl acetate, 
ß-ocimene, terpinen-4-ol, 1,8-cineole, and camphor, but the 
percentage of single constituents varies in different species 
(Cavanagh and Wilkinson, 2002; Woronuk et  al., 2011). In 
this study, the major components of LEO were linalyl acetate 
and linalool, accordingly to what described for the composition 
of lavender oil, obtained from the flowers of L. angustifolia 
(Cavanagh and Wilkinson, 2002).
Essential oils containing linalool and linalyl acetate as major 
volatile constituents, such as bergamot (Citrus bergamia) and 
yarrow (Achillea millefolium L.) essential oils, or purified linalool, 
showed the capability to reduce ERK and JNK phosphorylation 
and counteracted the induction of iNOS (Peana et  al., 2006; 
Chou et  al., 2013; Kuwahata et  al., 2013; Peng et  al., 2014), 
suggesting that these components might be prominently involved 
in the molecular mechanism of the antihyperalgesic activity 
of LEO.
Lavender has a long history of medicinal use as 
antidepressive, anxiolytic, sedative, and calming therapy 
(Cavanagh and Wilkinson, 2002; Koulivand et  al., 2013), 
properties that have been confirmed by some recent clinical 
trials (Akhondzadeh et  al., 2003; Woelk and Schläfke, 2010; 
Conrad and Adams, 2012) as well as preclinical works 
explaining molecular mechanisms of action (López et  al., 
2017). Neuropathic pain has been associated with a worse 
quality of life than general population (Doth et  al., 2010), 
largely due to the presence of comorbidities, such as poor 
sleep, anxiety, and depression, producing a high socioeconomic 
impact on society (Langley et  al., 2013; Torta et  al., 2017). 
We, thus, tested the efficacy of LEO in an anxiety-inducing 
environment and in a behavioral despair paradigm. Oral 
administration of LEO promoted an antidepressant-like and 
anxiolytic-like activity when administered at antihyperalgesic 
doses. The capability of LEO to positively modulate anxiety 
and mood simultaneously to the antinociceptive activity 
would greatly improve the overall symptomatology of 
neuropathic pain patients with relevant clinical benefit. 
Treatments for mood disorders are often accompanied by 
weight gain. Conversely, LEO at active doses reduced food 
consumption, representing a clinical advantage in case of 
long-term therapies.
LEO induced its antihyperalgesic effect in the absence 
of any visible alteration of locomotor behavior or other 
adverse behavioral effect. These findings show that 
oral administration of this essential oil can produce a sustained 
pain relief accompanied by an encouraging tolerability profile. 
Our positive results are supported by the available literature 
data. LEO has been granted Generally Recognized as 
Safe status by the Food and Drug Administration 
(21CFR182.202015), as indication of its safety when used 
as a dietary supplement (Food and Drug Administration, 
2016). The oral administration of many essential oils in 
their undiluted form is not recommended due to their 
irritant, inflammatory, or cytotoxic effects, requiring 
dilution or even avoidance. LEO is usually used in an 
undiluted form (topically or orally) and it appears to be well 
tolerated. Poisoning by lavender is uncommon. In mice, the 
oral LD50 is 13.5  ±  0.9  g/kg (Jenner et  al., 1964). Even 
though observational studies and long-term trials are necessary 
to establish the safety of long-term use of LEO for 
the treatment of neurological disorders, short-term 
therapy is considered safe (Koulivand et  al., 2013), further 
confirming the encouraging safety profile observed in the 
present study.
In conclusion, we demonstrated that the oral administration 
of LEO reduced SNI-induced neuropathic pain symptoms 
in  mice. These effects appeared simultaneously to an 
antidepressant-like and anxiolytic-like activity, at doses devoid 
of behavioral side effects. Our data suggest that inhibition of 
spinal ERK and JNK phosphorylation, and the reduction of 
iNOS expression by oral LEO may be  involved in 
antineuropathic effects. Oral administration of LEO might 
represent a therapeutic perspective in the management of 
neuropathic pain conditions.
ETHICS STATEMENT
The experimental protocol was carried out after approval 
by the Animal Care and Research Ethics Committee of the 
University of Florence, Italy, under license from the Italian 
Department of Health (54/2014-B) and in compliance with 
international laws and policies (Directive 2010/63/EU of the 
European parliament and of the council of 22 September 
Sanna et al. Lavender Oil in Neuropathic Pain
Frontiers in Pharmacology | www.frontiersin.org 12 May 2019 | Volume 10 | Article 472
2010 on the protection of animals used for scientific purposes; 
Guide for the Care and Use of Laboratory Animals, US 
National Research Council, 2011). All studies involving 
animals are reported in accordance with the ARRIVE 
guidelines for experiments involving animals.
AUTHOR CONTRIBUTIONS
MS and FL performed the in vivo experiments and the data 
analysis. VL performed the in vitro endocannabinoid bioassay, 
supervised the manuscript, supplied and analyzed the sample 
of lavender essential oil. NG conceived the study, set up the 
protocols, and wrote the manuscript.
FUNDING
The experimental work was mainly supported by grants from 
the Università degli Studi di Firenze. Pranarom International 
and Universidad San Jorge are also thanked for financial support 
(open access fee). The research stay of FL in Florence was 
funded by grants from the Univerdad San Jorge and Ibercaja.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online 
at: https://www.frontiersin.org/articles/10.3389/fphar.2019.00472/
full#supplementary-material
 
REFERENCES
Ahlawat, A., Rana, A., Goyal, N., and Sharma, S. (2014). Potential role of 
nitric oxide synthase isoforms in pathophysiology of neuropathic pain. 
Inflammopharmacology 22, 269–278. doi: 10.1007/s10787-014-0213-0
Ahlawat, A., and Sharma, S. (2018). A new promising simultaneous approach 
for attenuating type II diabetes mellitus induced neuropathic pain in rats: 
iNOS inhibition and neuroregeneration. Eur. J. Pharmacol. 818, 419–428. 
doi: 10.1016/j.ejphar.2017.11.010
Akhondzadeh, S., Kashani, L., Fotouhi, A., Jarvandi, S., Mobaseri, M., Moin, M., 
et al. (2003). Comparison of Lavandula angustifolia Mill. tincture and 
imipramine in the treatment of mild to moderate depression: a double-blind, 
randomized trial. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27, 123–127. 
doi: 10.1016/S0278-5846(02)00342-1
Austin, P. J., and Moalem Taylor, G. (2010). The neuroimmune balance in neuropathic 
pain: involvement of inflammatory immune cell, immune-like glia cells and 
cytokines. J. Neuroimmunol. 229, 26–50. doi: 10.1016/j.jneuroim.2010.08.013
Barić, H., Đorđević, V., Cerovečki, I., and Trkulja, V. (2018). Complementary 
and alternative medicine treatments for generalized anxiety disorder: systematic 
review and meta-analysis of randomized controlled trials. Adv. Ther. 35, 
261–288. doi: 10.1007/s12325-018-0680-6
Bourin, M., and Hascoët, M. (2003). The mouse light/dark box test. Eur. J. 
Pharmacol. 463, 55–65. doi: 10.1016/S0014-2999(03)01274-3
Bourquin, A. F., Süveges, M., Pertin, M., Gilliard, N., Sardy, S., Davison, A. C., 
et al. (2006). Assessment and analysis of mechanical allodynia-like behavior 
induced by spared nerve injury (SNI) in the mouse. Pain 122, 14.e1–14.e14. 
doi: 10.1016/j.pain.2005.10.036
Buckle, J. (2014). Clinical aromatherapy: Essential oils in practice. (Churchill 
Livingstone: Elsevier Health Sciences).
Calvo, M., Dawes, J. M., and Bennet, D. L. H. (2012). The role of the immune 
system in the generation of neuropathic pain. Lancet Neurol. 11, 629–642. 
doi: 10.1016/S1474-4422(12)70134-5
Cavanagh, H. M., and Wilkinson, J. M. (2002). Biological activities of lavender 
essential oil. Phytother. Res. 16, 301–308. doi: 10.1002/ptr.1103
Charan, J., and Kantharia, N. D. (2013). How to calculate sample size in animal 
studies? J. Pharmacol. Pharmacother. 4, 303–306. doi: 10.4103/0976-500X.119726
Chiurchiù, V., van der Stelt, M., Centonze, D., and Maccarrone, M. (2018). 
The endocannabinoid system and its therapeutic exploitation in multiple 
sclerosis: clues for other neuroinflammatory diseases. Prog. Neurobiol. 160, 
82–100. doi: 10.1016/j.pneurobio.2017.10.007
Chou, S. T., Peng, H. Y., Hsu, J. C., Lin, C. C., and Shih, Y. (2013). Achillea 
millefolium L. essential oil inhibits LPS-induced oxidative stress and nitric 
oxide production in RAW 264.7 macrophages. Int. J. Mol. Sci. 14, 12978–
12993. doi: 10.3390/ijms140712978
Cohen, S. P., and Mao, J. (2014). Neuropathic pain: mechanisms and their 
clinical implications. BMJ 348:f7656. doi: 10.1136/bmj.f7656
Conrad, P., and Adams, C. (2012). The effects of clinical aromatherapy for 
anxiety and depression in the high risk postpartum woman—a pilot study. 
Complement. Ther. Clin. Pract. 18, 164–168. doi: 10.1016/j.ctcp.2012.05.002
Daulhac, L., Mallet, C., Courteix, C., Etienne, M., Duroux, E., Privat, A. M., 
et al. (2006). Diabetes-induced mechanical hyperalgesia involves spinal 
mitogen-activated protein kinase activation in neurons and microglia via 
N-methyl-D-aspartate-dependent mechanisms. Mol. Pharmacol. 70, 1246–1254. 
doi: 10.1124/mol.106.025478
De Alba, J., Clayton, N. M., Collins, S. D., Colthup, P., Chessell, I., and 
Knowles, R. G. (2006). GW274150, a novel and highly selective inhibitor 
of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic 
effects in rat models of inflammatory and neuropathic pain. Pain 120, 
170–181. doi: 10.1016/j.pain.2005.10.028
Djenane, D., Aïder, M., Yangüela, J., Idir, L., Gómez, D., and Roncalés, P. 
(2012). Antioxidant and antibacterial effects of Lavandula and Mentha 
essential oils in minced beef inoculated with E. coli O157: H7 and S. aureus 
during storage at abuse refrigeration temperature. Meat Sci. 92, 667–674. 
doi: 10.1016/j.meatsci.2012.06.019
Doth, A. H., Hansson, P. T., Jensen, M. P., and Taylor, R. S. (2010). The 
burden of neuropathic pain: a systematic review and meta-analysis of health 
utilities. Pain 149, 338–344. doi: 10.1016/j.pain.2010.02.034
Edelmayer, R. M., Brederson, J. D., Jarvis, M. F., and Bitner, R. S. (2014). 
Biochemical and pharmacological assessment of MAP-kinase signaling along 
pain pathways in experimental rodent models: a potential tool for the 
discovery of novel antinociceptive therapeutics. Biochem. Pharmacol. 87, 
390–398. doi: 10.1016/j.bcp.2013.11.019
Eftekharsadat, B., Roomizadeh, P., Torabi, S., Heshmati-Afshar, F., Jahanjoo, F., 
and Babaei-Ghazani, A. (2017). Effectiveness of Lavendula stoechas essential 
oil in treatment of mild to moderate carpal tunnel syndrome: a randomized 
controlled trial. J. Hand Ther. 31, 437–442. doi: 10.1016/j.jht.2017.07.004
Ekor, M. (2014). The growing use of herbal medicines: issues relating to adverse 
reactions and challenges in monitoring safety. Front. Pharmacol. 4:177. doi: 
10.3389/fphar.2013.00177
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., 
et al. (2015). Pharmacotherapy for neuropathic pain in adults: a systematic 
review and meta-analysis. Lancet Neurol. 14, 162–173. doi: 10.1016/
S1474-4422(14)70251-0
Food and Drug Administration. (2016). [Internet]. 21CFR182.20–Code of Federal 
Regulations Title 2. Silver Spring (MD): Food and Drug Administration. 
Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/
CFRSearch.cfm?fr¼182.20 [Accessed October 1, 2016].
Galeotti, N., Bartolini, A., and Ghelardini, C. (2003). The phospholipase C-IP3 
pathway is involved in muscarinic antinociception. Neuropsychopharmacology 
28, 888–897. doi: 10.1038/sj.npp.1300111
Galeotti, N., and Ghelardini, C. (2012). Regionally selective activation and 
differential regulation of ERK, JNK and p38 MAP kinase signalling pathway 
by protein kinase C in mood modulation. Int. J. Neuropsychopharmacol. 
15, 781–793. doi: 10.1017/S1461145711000897
Gustorff, B., Dorner, T., Likar, R., Grisold, W., Lawrence, K., Schwarz, F., et  al. 
(2008). Prevalence of self-reported neuropathic pain and impact on quality 
of life: a prospective representative survey. Acta Anaesthesiol. Scand. 52, 
132–136. doi: 10.1111/j.1399-6576.2007.01486.x
Sanna et al. Lavender Oil in Neuropathic Pain
Frontiers in Pharmacology | www.frontiersin.org 13 May 2019 | Volume 10 | Article 472
He, Z. W., Wei, W., Li, S. P., Ling, Q., Liao, K. J., and Wang, X. (2014). Anti-
allodynic effects of obtusifolin and gluco-obtusifolin against inflammatory 
and neuropathic pain. Biol. Pharm. Bull. 37, 1606–1616. doi: 10.1248/bpb.
c14-00307
Jancálek, R., Dubový, P., Svízenská, I., and Klusáková, I. (2010). Bilateral changes 
of TNF-alpha and IL-10 protein in the lumbar and cervical dorsal root 
ganglia following a unilateral chronic constriction injury of the sciatic nerve. 
J. Neuroinflammation 7:11. doi: 10.1186/1742-2094-7-11
Jenner, P. M., Hagan, E. C., Taylor, J. M., Cook, E. L., and Fitzhugh, O. G. 
(1964). Food flavourings and compounds of related structure, I: acute oral 
toxicity. Food Cosmet. Toxicol. 2, 327–343. doi: 10.1016/S0015-6264(64)80192-9
Ji, R. R., Gereau, R. W. IV, Malcangio, M., and Strichartz, G. R. (2009). MAP 
kinase and pain. Brain Res. Rev. 60, 135–148. doi: 10.1016/j.
brainresrev.2008.12.011
Kleinert, H., Pautz, A., Linker, K., and Schwarz, P. M. (2004). Regulation of 
the expression of inducible nitric oxide synthase. Eur. J. Pharmacol. 500, 
255–266. doi: 10.1016/j.ejphar.2004.07.030
Koulivand, P. H., Khaleghi Ghadiri, M., and Gorji, A. (2013). Lavender and 
the nervous system. Evid. Based Complement. Alternat. Med. 2013:681304. 
doi: 10.1155/2013/681304
Kuwahata, H., Komatsu, T., Katsuyama, S., Corasaniti, M. T., Bagetta, G., 
Sakurada, S., et al. (2013). Peripherally injected linalool and bergamot essential 
oil attenuate mechanical allodynia via inhibiting spinal ERK phosphorylation. 
Pharmacol. Biochem. Behav. 103, 735–741. doi: 10.1016/j.pbb.2012.11.003
Kyle, G. (2006). Evaluating the effectiveness of aromatherapy in reducing levels 
of anxiety in palliative care patients: results of a pilot study. Complement. 
Ther. Clin. Pract. 12, 148–155. doi: 10.1016/j.ctcp.2005.11.003
LaBuda, C. J., Koblish, M., Tuthill, P., Dolle, R. E., and Little, P. J. (2006). 
Antinociceptive activity of the selective iNOS inhibitor AR-C102222 in rodent 
models of inflammatory, neuropathic and post-operative pain. Eur. J. Pain 
10, 505–512. doi: 10.1016/j.ejpain.2005.07.004
Langley, P. C., Van Litsenberg, C., Cappelleri, J. C., and Carroll, D. (2013). 
The burden associated with neuropathic pain in Western Europe. J. Med. 
Econ. 16, 85–95. doi: 10.3111/13696998.2012.729548
Lee, M. K., Han, S. R., Park, M. K., Kim, M. J., Bae, Y. C., Kim, S. K., et  al. 
(2011). Behavioral evidence for the differential regulation of p-p38 MAPK 
and p-NF-kappaB in rats with trigeminal neuropathic pain. Mol. Pain 7:57. 
doi: 10.1186/1744-8069-7-57
López, V., Nielsen, B., Solas, M., Ramírez, M. J., and Jäger, A. K. (2017). 
Exploring pharmacological mechanisms of Lavender (Lavandula angustifolia) 
essential oil on central nervous system targets. Front. Pharmacol. 8:280. doi: 
10.3389/fphar.2017.00280
Martucci, C., Trovato, A. E., Costa, B., Borsani, E., Franchi, S., Magnaghi, V., 
et al. (2008). The purinergic antagonist PPADS reduces pain related behaviours 
and interleukin-1beta, interleukin-6, iNOS and nNOS overproduction in 
central and peripheral nervous system after peripheral neuropathy in mice. 
Pain 137, 81–95. doi: 10.1016/j.pain.2007.08.017
McGrath, J. C., and Lilley, E. (2015). Implementing guidelines on reporting 
research using animals (ARRIVE etc.): new requirements for publication 
in BJP. Br. J. Pharmacol. 172, 3189–3193. doi: 10.1111/bph.12955
Mincheva-Tasheva, S., and Soler, R. M. (2013). NF-kB signaling pathways: role 
in nervous system physiology and pathology. Neuroscientist 19, 175–194. 
doi: 10.1177/1073858412444007
Nasiri, A., Mahmodi, M. A., and Nobakht, Z. (2016). Effect of aromatherapy 
massage with lavender essential oil on pain in patients with osteoarthritis 
of the knee: a randomized controlled clinical trial. Complement. Ther. Clin. 
Pract. 25, 75–80. doi: 10.1016/j.ctcp.2016.08.002
Okamura, N., Garau, C., Duangdao, D. M., Clark, S. D., Jüngling, K., Pape, H. C., 
et al. (2011). Neuropeptide S enhances memory during the consolidation 
phase and interacts with noradrenergic systems in the brain. 
Neuropsychopharmacology 36, 744–752. doi: 10.1038/npp.2010.207
Olapour, A., Behaeen, K., Akhondzadeh, R., Soltani, F., Al Sadat Razavi, F., 
and Bekhradi, R. (2013). The effect of inhalation of aromatherapy blend 
containing lavender essential oil on cesarean postoperative pain. Anesth. 
Pain Med. 3, 203–207. doi: 10.5812/aapm.9570
Ou, M. C., Hsu, T. F., Lai, A. C., Lin, Y. T., and Lin, C. C. (2012). Pain relief 
assessment by aromatic essential oil massage on outpatients with primary 
dysmenorrhea: a randomized, double-blind clinical trial. J. Obstet. Gynaecol. 
Res. 38, 817–822. doi: 10.1111/j.1447-0756.2011.01802.x
Peana, A. T., Marzocco, S., Popolo, A., and Pinto, A. (2006). (−)-Linalool 
inhibits in  vitro NO formation: probable involvement in the antinociceptive 
activity of this monoterpene compound. Life Sci. 78, 719–723. doi: 10.1016/j.
lfs.2005.05.065
Peng, H. Y., Lin, C. C., Wang, H. Y., Shih, Y., and Chou, S. T. (2014). The 
melanogenesis alteration effects of Achillea millefolium L. essential oil and 
linalyl acetate: involvement of oxidative stress and the JNK and ERK signaling 
pathways in melanoma cells. PLoS One 9:e95186. doi: 10.1371/journal.
pone.0116026
Sanna, M. D., Ghelardini, C., and Galeotti, N. (2015). Activation of JNK pathway 
in spinal astrocytes contributes to acute ultra-low dose morphine thermal 
hyperalgesia. Pain 156, 1265–1275. doi: 10.1097/j.pain.0000000000000164
Schmidtko, A., Tegeder, I., and Geisslinger, G. (2009). No NO, no pain? The 
role of nitric oxide and cGMP in spinal pain processing. Trends Neurosci. 
32, 339–346. doi: 10.1016/j.tins.2009.01.010
Scott, K. M., Bruffaerts, R., Tsang, A., Ormel, J., Alonso, J., Angermeyer, M., 
et al. (2007). Depression–anxiety relationships with chronic physical conditions: 
results from the world mental health surveys. J. Affect. Disord. 103, 113–120. 
doi: 10.1016/j.jad.2007.01.015
Soltani, R., Soheilipour, S., Hajhashemi, V., Asghari, G., Bagheri, M., and 
Molavi, M. (2013). Evaluation of the effect of aromatherapy with lavender 
essential oil on post-tonsillectomy pain in pediatric patients: a randomized 
controlled trial. Int. J. Pediatr. Otorhinolaryngol. 77, 1579–1581. doi: 10.1016/j.
ijporl.2013.07.014
Torta, R., Ieraci, V., and Zizzi, F. (2017). A review of the emotional aspects 
of neuropathic pain: from comorbidity to co-pathogenesis. Pain Ther. 
6(Suppl.  1), 11–17. doi: 10.1007/s40122-017-0088-z
Tsang, A., Von Korff, M., Lee, S., Alonso, J., Karam, E., Angermeyer, M. C., 
et al. (2008). Common chronic pain conditions in developed and developing 
countries: gender and age differences and comorbidity with depression-
anxiety disorders. J. Pain 9, 883–891. doi: 10.1016/j.jpain.2008.05.005
Vranken, J. H. (2012). Elucidation of pathophysiology and treatment of 
neuropathic pain. Cent. Nerv. Syst. Agents Med. Chem. 12, 304–314. doi: 
10.2174/187152412803760645
Woelk, H., and Schläfke, S. (2010). A multi-center, double-blind, randomised 
study of the Lavender oil preparation Silexan in comparison to Lorazepam 
for generalized anxiety disorder. Phytomedicine 17, 94–99. doi: 10.1016/j.
phymed.2009.10.006
Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., and Neugebauer, V. 
(2017). The cannabinoid system and pain. Neuropharmacology 124, 105–120. 
doi: 10.1016/j.neuropharm.2017.06.015
Woronuk, G., Demissie, Z., Rheault, M., and Mahmoud, S. (2011). Biosynthesis 
and therapeutic properties of Lavandula essential oil constituents. Planta 
Med. 77, 7–15. doi: 10.1055/s-0030-1250136
Yazdkhasti, M., and Pirak, A. (2016). The effect of aromatherapy with lavender 
essence on severity of labor pain and duration of labor in primiparous 
women. Complement. Ther. Clin. Pract. 25, 81–86. doi: 10.1016/j.ctcp.2016.08.008
Zhou, C., Shi, X., Huang, H., Zhu, Y., and Wu, Y. (2014). Montelukast attenuates 
neuropathic pain through inhibiting p38 mitogen-activated protein kinase 
and nuclear factor-kappa B in a rat model of chronic constriction injury. 
Anesth. Analg. 118, 1090–1096. doi: 10.1213/ANE.0000000000000174
Zhuang, Z. Y., Wen, Y. R., Zhang, D. R., Borsello, T., Bonny, C., Strichartz, G. R., 
et al. (2006). A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks 
mechanical allodynia after spinal nerve ligation: respective roles of JNK 
activation in primary sensory neurons and spinal astrocytes for neuropathic 
pain development and maintenance. J. Neurosci. 26, 3551–3560. doi: 10.1523/
JNEUROSCI.5290-05.2006
Conflict of Interest Statement: Universidad San Jorge has received financial 
support from Pranarom for research purposes. The funders had no role in study 
design, data collection, analysis, decision to publish, or preparation of the manuscript.
Copyright © 2019 Sanna, Les, Lopez and Galeotti. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) and the copyright owner(s) are credited and that the original 
publication in this journal is cited, in accordance with accepted academic practice. 
No use, distribution or reproduction is permitted which does not comply with 
these terms.
